EP3795592
Bestun á mótefnum sem binda eitilfrumu-virkjunargen-3 (LAG-3), og notkun á þeim
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
2.7.2013EP published:
24.7.2024EP application number:
20192145.9
EP translation filed:
30.9.2024Grant published:
15.11.2024EPO information:
European Patent Register
Max expiry date:
1.7.2033Expiry date:
1.7.2026Next due date:
31.7.2026
Title in English:
OPTIMIZATION OF ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOFLanguage of the patent:
English
Timeline
Today
2.7.2013EP application
24.7.2024EP Publication
30.9.2024Translation submitted
15.11.2024Registration published
1.7.2026Expires
Owner
Name:
Bristol-Myers Squibb CompanyAddress:
Route 206 and Province Line Road, Princeton, NJ 08543, US
Inventor
Name:
LONBERG, NilsAddress:
Redwood City, CA 94063, US
Name:
SRINIVASAN, MohanAddress:
Redwood City, CA 94063, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201261667058 PDate:
2.7.2012Country:
US
Classification
Categories:
A61K 45/06, A61P 31/12, A61P 35/00, A61P 37/02, A61P 37/04, C07K 16/28
Annual fees
Number
Paid
Expires
Payer
Number: 13
Paid: 4.7.2025
Expires: 1.7.2026
Payer: Árnason Faktor ehf.